|
|
|
|
|
|
BMP: Health Advances developed positioning strategies and pricing recommendations for product line extensions in trauma, spine, and
degenerative disc disease populations. Qualitative interviews and a quantitative analysis including conjoint were used. The study considered competitive
threats from all the existing competitors as well as likely new entrants.
Bioresorbable Bone Cement: A private early-stage company was seeking to better understand the market opportunity for its bioresorbable bone
cement. Heath Advances outlined which indications would provide the best lead candidate versus the best overall market opportunity. The assessment covered
market sizing in cranio-maxillofacial, dental, spinal, and general orthopedic markets.
Orthopedic Implant Components: Health Advances worked with a private equity firm to evaluate an acquisition in the orthopedic implant
component market. The study assessed the evolution of materials and designs likely to grow and shrink in the next ten years. This assessment helped
project the market demand for the subset of components made by the target company and provided insights into which OEM customers were best leveraged
to target for increased sales and those that were likely to decrease orders due to design and material changes.
Corrective Procedures for Treatment of Damaged Knee Cartilage: Health Advances identified and analyzed a large research database developed
by a leading orthopedic surgeon to assess the frequency of different corrective procedures for damaged knee cartilage and their outcomes. The Health
Advances team captured quantitative and qualitative measures of outcomes, including timing to subsequent treatments. This information was combined with
findings from orthopedic surgeon interviews to document current clinical pathways by patient segment. Subsequently, the economics of a novel therapeutic
procedure were quantified, assuming a range of clinical success rates as documented in the database and published literature. This work was included in
the BLA filed with the FDA, which was approved.
Diagnostic for Soft Tissue Musculoskeletal Injuries: Health Advances was asked to assess the annual market size of soft-tissue
musculoskeletal injuries in terms of volume of tests, to examine the potential cost effectiveness of the device in different patient populations,
and to test the concept of a MDSN strategy, whereby the client would establish provider networks to address patients with musculoskeletal injuries
and to boost use of the client's device. This diagnostic was initially being used to evaluate the source of cervical and lumbar pain, both where the
problem was and as a way to identify malingerers who really did not have a problem (a concern with prolonged workers' compensation cases).
Osteoporosis and Estrogen Replacement: Working closely with an investor group, Health Advances supported a market evaluation and planning
effort for a new company to be formed around breakthrough technology targeting the estrogen receptor and its role in osteoporosis. In addition to
addressing some of the technical questions underlying the opportunity, Health Advances also examined the role of estrogen replacement therapy in
post-menopausal women, the potential impact of the Women's Health Initiative Study, and competitive product development efforts.
|
|
 |
|
|
|
|
